ECSP056023A - Métodos para aislar la forma cristalina I de la 5-azacitidina - Google Patents

Métodos para aislar la forma cristalina I de la 5-azacitidina

Info

Publication number
ECSP056023A
ECSP056023A EC2005006023A ECSP056023A ECSP056023A EC SP056023 A ECSP056023 A EC SP056023A EC 2005006023 A EC2005006023 A EC 2005006023A EC SP056023 A ECSP056023 A EC SP056023A EC SP056023 A ECSP056023 A EC SP056023A
Authority
EC
Ecuador
Prior art keywords
azacitidine
methods
crystalline form
isolating crystalline
provides
Prior art date
Application number
EC2005006023A
Other languages
English (en)
Inventor
Ionescu Dumitru
Blumbergs Peter
L Silvey Gary
Original Assignee
Pharmion Corp
Ash Stevens Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32987551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP056023(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmion Corp, Ash Stevens Inc filed Critical Pharmion Corp
Publication of ECSP056023A publication Critical patent/ECSP056023A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona los métodos para robustecer y para reproducir aislante 5 - azacitidina como el polifórmico forma I substancialmente libre de otras fórmulas. Los métodos involucran los recristalizadores disueltos en 5 - azacitidina desde una mezcla solvente primaria y luego coleccionando los cristales del resultante. La invención también proporciona composiciones farmacéuticas que comprenden la Forma I de 5 azacitidina junto con un vehículo, diluyente o excipiente farmacéutico aceptable.
EC2005006023A 2003-03-17 2005-09-16 Métodos para aislar la forma cristalina I de la 5-azacitidina ECSP056023A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/390,530 US6943249B2 (en) 2003-03-17 2003-03-17 Methods for isolating crystalline Form I of 5-azacytidine

Publications (1)

Publication Number Publication Date
ECSP056023A true ECSP056023A (es) 2006-01-27

Family

ID=32987551

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006023A ECSP056023A (es) 2003-03-17 2005-09-16 Métodos para aislar la forma cristalina I de la 5-azacitidina

Country Status (16)

Country Link
US (5) US6943249B2 (es)
EP (3) EP1608634B1 (es)
JP (1) JP4792550B2 (es)
AU (2) AU2004222274B2 (es)
BR (1) BRPI0408506A (es)
CA (1) CA2518973A1 (es)
CY (2) CY1114213T1 (es)
DK (2) DK2181988T3 (es)
EC (1) ECSP056023A (es)
ES (2) ES2575535T3 (es)
HU (1) HUE028268T2 (es)
MX (1) MXPA05009969A (es)
PL (2) PL1608634T3 (es)
PT (2) PT1608634E (es)
SI (2) SI1608634T1 (es)
WO (1) WO2004082822A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8902490A (nl) * 1989-10-06 1991-05-01 Leonardus Mathijs Marie Nevels Werkwijze voor het reinigen van rookgassen.
EP1300992B1 (en) * 2001-10-08 2005-12-28 Alcatel Method for distributing load over multiple shared resources in a communication network and network applying such a method
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008088779A2 (en) * 2007-01-11 2008-07-24 Ivax Pharmaceuticals S.R.O. Solid state forms of 5-azacytidine and processes for preparation thereof
US20110288042A1 (en) * 2007-08-02 2011-11-24 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
WO2009042767A1 (en) * 2007-09-26 2009-04-02 Mount Sinai School Of Medicine Azacytidine analogues and uses thereof
EP2211870A1 (en) * 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
PL3692983T3 (pl) * 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2010014883A2 (en) 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
JP5650643B2 (ja) * 2008-08-08 2015-01-07 サイノファーム タイワン リミテッド ５−アザシトシンヌクレオシド及びその誘導体の製造方法
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr PREPARATION OF DECITABIN
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
CN103619864A (zh) * 2011-03-31 2014-03-05 细胞基因国际有限公司 5-氮杂胞苷的合成
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
CA2849708A1 (en) 2011-09-23 2013-03-28 Celgene Corporation Romidepsin and 5 - azacitidine for use in treating lymphoma
CA2849903A1 (en) 2011-09-26 2013-04-04 Celgene Corporation Combination therapy for chemoresistant cancers
KR101987861B1 (ko) 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
WO2013080221A2 (en) * 2011-12-01 2013-06-06 Hetero Research Foundation Process for alvimopan
US9669048B2 (en) * 2012-10-25 2017-06-06 Fresenius Kabi Oncology Limited Stable pharmaceutical composition of 5-aza-2′-deoxycitidine
WO2014076616A2 (en) * 2012-11-19 2014-05-22 Shilpa Medicare Limited Formulations of 5-azacytidine
US9765108B2 (en) 2012-11-19 2017-09-19 Shilpa Medicare Limited Formulation of 5-azacytidine
WO2014160698A1 (en) 2013-03-26 2014-10-02 Celgene Corporation SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
CN103450303A (zh) * 2013-09-04 2013-12-18 重庆泰濠制药有限公司 阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US20160095925A1 (en) * 2014-10-01 2016-04-07 Cadila Healthcare Limited Stable formulation of azacitidine or salts thereof and their process for preparation
US10695352B2 (en) 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
KR102699521B1 (ko) 2015-10-15 2024-08-26 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
EP3527226A4 (en) * 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR
CN109988207B (zh) * 2017-12-29 2022-01-04 江苏豪森药业集团有限公司 阿扎胞苷晶型的制备方法
US10632211B2 (en) 2018-06-11 2020-04-28 The Regents Of The University Of California Demethylation to treat eye disease
CN110642901A (zh) * 2019-11-11 2020-01-03 扬子江药业集团有限公司 阿扎胞苷甲醇化物及其制备方法和药物组合物、用途
US20240262857A1 (en) * 2021-05-27 2024-08-08 Emory University Novel universal anti-rna virus agents
WO2026068588A1 (en) 2024-09-30 2026-04-02 Synthon B.V. Improved azacitidine composition

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (es) * 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) * 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) * 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) * 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) * 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
US5700640A (en) 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
ATE238328T1 (de) 1996-10-16 2003-05-15 Ribapharm Inc Monozyklische l-nukleoside, analoga und ihre anwendungen
WO2000075143A1 (en) * 1999-06-03 2000-12-14 Eisai Co., Ltd. Crystals of carbapenem derivatives and pharmaceutical preparations for injection
CA2374737C (en) 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
EP1248869A2 (en) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2002020453A1 (en) 2000-09-07 2002-03-14 Kaneka Corporation Methods for crystallization of hydroxycarboxylic acids
CN102942563A (zh) * 2001-03-01 2013-02-27 基利得科学公司 顺-ftc的多晶型物及其它晶型
CA2499036A1 (en) 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20040162263A1 (en) 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
CN1802352A (zh) 2003-02-03 2006-07-12 特瓦制药工业有限公司 制备左乙拉西坦的方法
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6877855B2 (en) 2003-07-08 2005-04-12 Dave Ng Spectacles with peripheral lens support
CN102349927A (zh) 2003-08-29 2012-02-15 Hdac默克研究有限责任公司 联合治疗癌症的方法
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
WO2008088779A2 (en) 2007-01-11 2008-07-24 Ivax Pharmaceuticals S.R.O. Solid state forms of 5-azacytidine and processes for preparation thereof
US20080182806A1 (en) 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
US20110288042A1 (en) 2007-08-02 2011-11-24 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
EP2211870A1 (en) 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2010014883A2 (en) 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2520581A1 (en) 2008-08-06 2012-11-07 Sicor, Inc. Method for the determination the purity of 5-Azacytidine
JP5650643B2 (ja) 2008-08-08 2015-01-07 サイノファーム タイワン リミテッド ５−アザシトシンヌクレオシド及びその誘導体の製造方法
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina

Also Published As

Publication number Publication date
WO2004082822A2 (en) 2004-09-30
PL1608634T3 (pl) 2013-10-31
MXPA05009969A (es) 2006-02-17
EP1608634A2 (en) 2005-12-28
DK2181988T3 (en) 2016-06-06
EP2181988A1 (en) 2010-05-05
HUE028268T2 (en) 2016-12-28
US20130274459A1 (en) 2013-10-17
DK1608634T3 (da) 2013-08-12
JP2006523210A (ja) 2006-10-12
US20120245342A1 (en) 2012-09-27
AU2010241198B2 (en) 2012-05-10
SI1608634T1 (sl) 2013-09-30
AU2004222274B2 (en) 2010-11-04
US7700770B2 (en) 2010-04-20
US8975392B2 (en) 2015-03-10
US8211862B2 (en) 2012-07-03
EP2181988B1 (en) 2016-05-11
CY1114213T1 (el) 2016-08-31
CY1117639T1 (el) 2017-04-26
EP1608634B1 (en) 2013-05-22
PT1608634E (pt) 2013-08-27
US20100292180A1 (en) 2010-11-18
US20040186284A1 (en) 2004-09-23
AU2010241198A1 (en) 2010-11-25
US6943249B2 (en) 2005-09-13
BRPI0408506A (pt) 2006-03-14
AU2004222274A1 (en) 2004-09-30
WO2004082822A3 (en) 2005-07-07
EP1608634A4 (en) 2006-03-15
PT2181988E (pt) 2016-06-15
ES2425474T3 (es) 2013-10-15
CA2518973A1 (en) 2004-09-30
EP2266965A1 (en) 2010-12-29
ES2575535T3 (es) 2016-06-29
PL2181988T3 (pl) 2016-11-30
US8481715B2 (en) 2013-07-09
US20050272675A1 (en) 2005-12-08
SI2181988T1 (sl) 2016-09-30
JP4792550B2 (ja) 2011-10-12

Similar Documents

Publication Publication Date Title
ECSP056023A (es) Métodos para aislar la forma cristalina I de la 5-azacitidina
CO5680428A2 (es) Antagonistas del receptor de trombina
ECSP056020A (es) Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion
AR106945A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
CL2019002919A1 (es) Compuestos inhibidores vmat2 y composiciones relacionadas.
TW200630461A (en) Organic electroluminescent device
CR8402A (es) Indazol-o-glucosidos sustitutos
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
GT200400133AA (es) Derivados de pirrolo[3,4-c] pirazol, activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. (solicitud fraccionaria no. 1, derivada de la patente no. pi-2004-0133).
ECSP066406A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CO6700838A2 (es) Compuestos sustituidos de banzamida
AR067316A1 (es) Moleculas secuestradoras de oxigeno, articulos que las contienen y metodos para su uso
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
UY27304A1 (es) Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
CR10937A (es) Inhibidores de cinasa mapk/erk
AR053336A1 (es) Formas cristalinas de un compuesto de bifenilo
UY27716A1 (es) Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo.
TW200722422A (en) Heterocyclic compound and organic electroluminescent device using the same
DOP2003000708A (es) Formulaciones que comprenden un compuesto a base de indolinona
AR063576A1 (es) Arilsulfonil- pirrolidinas como inhibidores 5-ht6
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
CR10974A (es) Inhibidores de carboxipeptidasa b plasmatica (divisional)
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
PA8574701A1 (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen